| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 10 | 2019 | 839 | 0.850 |
Why?
|
| Kidney | 7 | 2021 | 945 | 0.850 |
Why?
|
| Allografts | 1 | 2019 | 63 | 0.670 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 63 | 0.660 |
Why?
|
| Cytomegalovirus Infections | 1 | 2019 | 69 | 0.650 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 3 | 2009 | 15 | 0.650 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 57 | 0.530 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 142 | 0.500 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 129 | 0.500 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 274 | 0.500 |
Why?
|
| Autoantibodies | 4 | 2021 | 434 | 0.470 |
Why?
|
| Acute Kidney Injury | 3 | 2014 | 232 | 0.420 |
Why?
|
| Influenza, Human | 2 | 2012 | 79 | 0.420 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 508 | 0.400 |
Why?
|
| Serologic Tests | 1 | 2010 | 46 | 0.370 |
Why?
|
| Autoimmune Diseases | 2 | 2010 | 186 | 0.360 |
Why?
|
| Kidney Failure, Chronic | 3 | 2019 | 365 | 0.350 |
Why?
|
| Antiviral Agents | 2 | 2019 | 211 | 0.340 |
Why?
|
| Lupus Nephritis | 5 | 2021 | 193 | 0.320 |
Why?
|
| Biopsy | 5 | 2021 | 540 | 0.320 |
Why?
|
| Graft Rejection | 3 | 2019 | 458 | 0.310 |
Why?
|
| Cough | 1 | 2007 | 65 | 0.280 |
Why?
|
| Lymphoma, B-Cell | 2 | 2005 | 40 | 0.270 |
Why?
|
| Anemia | 1 | 2007 | 104 | 0.270 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1536 | 0.270 |
Why?
|
| Mediastinal Neoplasms | 1 | 2005 | 27 | 0.260 |
Why?
|
| Humans | 43 | 2021 | 68618 | 0.240 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2014 | 8 | 0.230 |
Why?
|
| Adenovirus Infections, Human | 1 | 2003 | 4 | 0.230 |
Why?
|
| Ribavirin | 1 | 2003 | 27 | 0.220 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2003 | 52 | 0.220 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2003 | 12 | 0.220 |
Why?
|
| Pancreas Transplantation | 1 | 2003 | 71 | 0.220 |
Why?
|
| Crohn Disease | 1 | 2003 | 38 | 0.220 |
Why?
|
| Adult | 18 | 2021 | 21403 | 0.210 |
Why?
|
| Graft Survival | 5 | 2019 | 465 | 0.200 |
Why?
|
| Tool Use Behavior | 1 | 2021 | 4 | 0.200 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 514 | 0.190 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2021 | 21 | 0.190 |
Why?
|
| Tacrolimus | 2 | 2019 | 127 | 0.190 |
Why?
|
| Pemphigoid, Bullous | 1 | 2021 | 13 | 0.190 |
Why?
|
| Middle Aged | 15 | 2021 | 21147 | 0.180 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 3 | 2012 | 15 | 0.180 |
Why?
|
| Complement C3 | 1 | 2021 | 101 | 0.180 |
Why?
|
| Immunoglobulin G | 3 | 2021 | 481 | 0.180 |
Why?
|
| Kidney Diseases | 2 | 2015 | 307 | 0.180 |
Why?
|
| Female | 22 | 2021 | 38074 | 0.180 |
Why?
|
| Biomarkers | 6 | 2021 | 1593 | 0.170 |
Why?
|
| Heart Transplantation | 2 | 2017 | 328 | 0.170 |
Why?
|
| Everolimus | 1 | 2019 | 26 | 0.170 |
Why?
|
| Proteinuria | 3 | 2014 | 136 | 0.170 |
Why?
|
| Liver Transplantation | 2 | 2017 | 400 | 0.160 |
Why?
|
| Retinal Vasculitis | 1 | 2018 | 8 | 0.160 |
Why?
|
| Behcet Syndrome | 1 | 2018 | 5 | 0.160 |
Why?
|
| Methimazole | 1 | 2018 | 9 | 0.160 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 10 | 0.160 |
Why?
|
| Retinal Artery | 1 | 2018 | 10 | 0.160 |
Why?
|
| Transplant Recipients | 1 | 2019 | 109 | 0.160 |
Why?
|
| Male | 21 | 2021 | 37321 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 144 | 0.150 |
Why?
|
| Skin | 1 | 2021 | 451 | 0.150 |
Why?
|
| Babesia | 1 | 2017 | 5 | 0.150 |
Why?
|
| Adolescent | 6 | 2019 | 8912 | 0.150 |
Why?
|
| Babesiosis | 1 | 2017 | 9 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2013 | 756 | 0.140 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2017 | 5 | 0.140 |
Why?
|
| Aftercare | 1 | 2018 | 114 | 0.140 |
Why?
|
| Mastocytosis | 1 | 2016 | 6 | 0.140 |
Why?
|
| Hepatitis | 1 | 2017 | 25 | 0.140 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 1465 | 0.140 |
Why?
|
| Visual Acuity | 1 | 2018 | 236 | 0.140 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2016 | 11 | 0.140 |
Why?
|
| Death, Sudden | 1 | 2016 | 24 | 0.140 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2016 | 20 | 0.140 |
Why?
|
| Podocytes | 2 | 2014 | 113 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2017 | 205 | 0.130 |
Why?
|
| Glomerulonephritis | 2 | 2008 | 77 | 0.130 |
Why?
|
| BK Virus | 1 | 2015 | 17 | 0.130 |
Why?
|
| Polyomavirus Infections | 1 | 2015 | 17 | 0.130 |
Why?
|
| Tumor Virus Infections | 1 | 2015 | 32 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1174 | 0.120 |
Why?
|
| Angiotensin I | 1 | 2014 | 24 | 0.120 |
Why?
|
| Proteasome Inhibitors | 1 | 2014 | 29 | 0.120 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2014 | 43 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2014 | 152 | 0.110 |
Why?
|
| Angiotensin II | 1 | 2014 | 220 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 92 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 504 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2016 | 631 | 0.110 |
Why?
|
| Thrombopoietin | 1 | 2013 | 15 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2008 | 511 | 0.110 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2012 | 14 | 0.110 |
Why?
|
| Peritoneum | 1 | 2012 | 27 | 0.100 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 23 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2007 | 489 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2014 | 483 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 1615 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 376 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 44 | 0.100 |
Why?
|
| Child | 6 | 2018 | 6405 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2019 | 7029 | 0.090 |
Why?
|
| Polymyositis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2010 | 9 | 0.090 |
Why?
|
| Dermatomyositis | 1 | 2010 | 31 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 36 | 0.090 |
Why?
|
| Immunophenotyping | 1 | 1990 | 110 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 320 | 0.090 |
Why?
|
| Antigens, Neoplasm | 2 | 1990 | 132 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2021 | 3705 | 0.090 |
Why?
|
| Antigens, Differentiation | 1 | 1990 | 49 | 0.090 |
Why?
|
| Nitrites | 2 | 2008 | 53 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2008 | 201 | 0.090 |
Why?
|
| Nitrates | 2 | 2008 | 61 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1990 | 70 | 0.090 |
Why?
|
| Bone Marrow | 1 | 1990 | 168 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2014 | 164 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2005 | 230 | 0.080 |
Why?
|
| Cryoglobulinemia | 1 | 2008 | 5 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 627 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2009 | 248 | 0.080 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2008 | 22 | 0.080 |
Why?
|
| Lysine | 1 | 2008 | 96 | 0.080 |
Why?
|
| Infant | 3 | 2021 | 2891 | 0.080 |
Why?
|
| Heart Failure | 1 | 2017 | 1180 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2008 | 87 | 0.080 |
Why?
|
| HLA-A Antigens | 1 | 2007 | 8 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 43 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1070 | 0.070 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 446 | 0.070 |
Why?
|
| Renal Insufficiency | 2 | 2008 | 121 | 0.070 |
Why?
|
| Antigen-Antibody Complex | 1 | 2007 | 175 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1753 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 778 | 0.070 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2005 | 5 | 0.060 |
Why?
|
| Hypertension | 1 | 2014 | 1535 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2018 | 3187 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 76 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 47 | 0.060 |
Why?
|
| Paclitaxel | 2 | 1995 | 140 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2021 | 7277 | 0.060 |
Why?
|
| Glomerular Mesangium | 1 | 2003 | 53 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 55 | 0.060 |
Why?
|
| Basement Membrane | 1 | 2003 | 48 | 0.060 |
Why?
|
| Ischemia | 1 | 2004 | 229 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 334 | 0.050 |
Why?
|
| Diarrhea | 1 | 2003 | 63 | 0.050 |
Why?
|
| Severity of Illness Index | 4 | 2013 | 1851 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2003 | 79 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2003 | 59 | 0.050 |
Why?
|
| Kidney Function Tests | 2 | 2019 | 114 | 0.050 |
Why?
|
| Nephritis, Hereditary | 1 | 2002 | 8 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 626 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3259 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 649 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2004 | 320 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2017 | 682 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2018 | 2455 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 44 | 0.050 |
Why?
|
| Prognosis | 2 | 2019 | 2093 | 0.050 |
Why?
|
| False Negative Reactions | 1 | 2021 | 63 | 0.050 |
Why?
|
| Liver | 2 | 2004 | 1118 | 0.040 |
Why?
|
| Factor V | 1 | 2000 | 20 | 0.040 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 9 | 0.040 |
Why?
|
| Renal Artery Obstruction | 1 | 2000 | 29 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 2000 | 57 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 4848 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2003 | 718 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2021 | 153 | 0.040 |
Why?
|
| Cyclosporine | 1 | 1999 | 121 | 0.040 |
Why?
|
| Aldosterone | 1 | 1999 | 51 | 0.040 |
Why?
|
| Tyrosine | 1 | 1999 | 196 | 0.040 |
Why?
|
| Young Adult | 3 | 2016 | 5717 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2000 | 125 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2014 | 216 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 274 | 0.040 |
Why?
|
| Nephrotic Syndrome | 1 | 1999 | 61 | 0.040 |
Why?
|
| Nephrectomy | 2 | 2014 | 103 | 0.040 |
Why?
|
| Antithyroid Agents | 1 | 2018 | 20 | 0.040 |
Why?
|
| Colitis | 1 | 1999 | 156 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 2018 | 33 | 0.040 |
Why?
|
| Fluorescein Angiography | 1 | 2018 | 57 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 1999 | 155 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 622 | 0.040 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2017 | 13 | 0.040 |
Why?
|
| Clindamycin | 1 | 2017 | 25 | 0.040 |
Why?
|
| Quinidine | 1 | 2017 | 15 | 0.040 |
Why?
|
| Blood Donors | 1 | 2017 | 18 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2017 | 329 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1999 | 185 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 1999 | 382 | 0.040 |
Why?
|
| T-Lymphocytes | 3 | 2017 | 597 | 0.040 |
Why?
|
| Chromogranin A | 1 | 2016 | 2 | 0.040 |
Why?
|
| Thymectomy | 1 | 2017 | 11 | 0.040 |
Why?
|
| Antimalarials | 1 | 2017 | 71 | 0.040 |
Why?
|
| Prostaglandin D2 | 1 | 2016 | 21 | 0.040 |
Why?
|
| Aged | 3 | 2021 | 14862 | 0.040 |
Why?
|
| Histamine | 1 | 2016 | 52 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 1056 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 94 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 546 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 255 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 202 | 0.030 |
Why?
|
| Sirolimus | 1 | 2017 | 118 | 0.030 |
Why?
|
| Heparin | 1 | 2016 | 205 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2017 | 219 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1995 | 88 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2077 | 0.030 |
Why?
|
| Splenosis | 1 | 1995 | 4 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1995 | 174 | 0.030 |
Why?
|
| Taxoids | 1 | 1995 | 41 | 0.030 |
Why?
|
| Rats | 3 | 2014 | 5300 | 0.030 |
Why?
|
| Teniposide | 1 | 2014 | 5 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2014 | 245 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 2014 | 109 | 0.030 |
Why?
|
| Hypertension, Renal | 1 | 2014 | 29 | 0.030 |
Why?
|
| Thalidomide | 1 | 2014 | 24 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2014 | 40 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5731 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 45 | 0.030 |
Why?
|
| Pyrazines | 1 | 2014 | 46 | 0.030 |
Why?
|
| Edema | 1 | 2014 | 66 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 215 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 129 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2014 | 101 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2003 | 1085 | 0.030 |
Why?
|
| Epitopes | 1 | 1994 | 146 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2014 | 150 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1990 | 27 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 326 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 2013 | 19 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.030 |
Why?
|
| Plasma Exchange | 1 | 2013 | 18 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 1995 | 307 | 0.030 |
Why?
|
| Influenza A virus | 1 | 2012 | 13 | 0.030 |
Why?
|
| Acute Disease | 2 | 2007 | 658 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 122 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 30 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 951 | 0.030 |
Why?
|
| Mosaicism | 1 | 2011 | 21 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 948 | 0.020 |
Why?
|
| Apoptosis | 2 | 1995 | 1641 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 306 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1992 | 149 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 468 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1038 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1990 | 6 | 0.020 |
Why?
|
| Lymphoma, T-Cell | 1 | 1990 | 19 | 0.020 |
Why?
|
| Rats, Wistar | 2 | 2003 | 371 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 1026 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 659 | 0.020 |
Why?
|
| Animals | 4 | 2014 | 20881 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1992 | 268 | 0.020 |
Why?
|
| Neprilysin | 1 | 1990 | 55 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 243 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1990 | 228 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2004 | 1040 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 786 | 0.020 |
Why?
|
| Cell Division | 2 | 2003 | 541 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 33 | 0.020 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2008 | 118 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2010 | 328 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 61 | 0.020 |
Why?
|
| United States | 2 | 2018 | 7367 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2008 | 171 | 0.020 |
Why?
|
| Phenotype | 1 | 1990 | 947 | 0.020 |
Why?
|
| Lymphoma | 1 | 1988 | 116 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 2334 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1990 | 1140 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 2550 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 172 | 0.020 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2005 | 3 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 50 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 1330 | 0.020 |
Why?
|
| Finger Joint | 1 | 2005 | 9 | 0.020 |
Why?
|
| Synovial Membrane | 1 | 2005 | 23 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 1046 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2004 | 14 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1054 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 351 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 1692 | 0.010 |
Why?
|
| Thioctic Acid | 1 | 2003 | 6 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2007 | 0.010 |
Why?
|
| Fatty Liver | 1 | 2004 | 97 | 0.010 |
Why?
|
| Isoantibodies | 1 | 2003 | 35 | 0.010 |
Why?
|
| Growth Substances | 1 | 2003 | 77 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1995 | 852 | 0.010 |
Why?
|
| South Carolina | 1 | 2010 | 2752 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 1603 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2003 | 126 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 250 | 0.010 |
Why?
|
| Transplantation, Homologous | 2 | 1994 | 242 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 4655 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 2791 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 562 | 0.010 |
Why?
|
| Antioxidants | 1 | 2003 | 304 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 2279 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 696 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 384 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 1200 | 0.010 |
Why?
|
| Renal Veins | 1 | 2000 | 18 | 0.010 |
Why?
|
| Renal Artery | 1 | 2000 | 29 | 0.010 |
Why?
|
| Superoxides | 1 | 1999 | 70 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1999 | 119 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1664 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1999 | 94 | 0.010 |
Why?
|
| Rats, Inbred WF | 1 | 1999 | 14 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 163 | 0.010 |
Why?
|
| Organ Size | 1 | 1999 | 242 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 306 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2673 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 1999 | 152 | 0.010 |
Why?
|
| Albuminuria | 1 | 1999 | 171 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 579 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 8474 | 0.010 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 1995 | 24 | 0.010 |
Why?
|
| Staurosporine | 1 | 1995 | 19 | 0.010 |
Why?
|
| G2 Phase | 1 | 1995 | 26 | 0.010 |
Why?
|
| S Phase | 1 | 1995 | 38 | 0.010 |
Why?
|
| Genistein | 1 | 1995 | 26 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1995 | 85 | 0.010 |
Why?
|
| Carcinogens | 1 | 1995 | 86 | 0.010 |
Why?
|
| Complement Hemolytic Activity Assay | 1 | 1995 | 4 | 0.010 |
Why?
|
| Mitogens | 1 | 1995 | 45 | 0.010 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1995 | 17 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1995 | 30 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1995 | 31 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1995 | 43 | 0.010 |
Why?
|
| Nucleosomes | 1 | 1995 | 25 | 0.010 |
Why?
|
| Splenectomy | 1 | 1995 | 40 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1995 | 32 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 95 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1995 | 93 | 0.010 |
Why?
|
| Mitosis | 1 | 1995 | 76 | 0.010 |
Why?
|
| Microtubules | 1 | 1995 | 104 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 1213 | 0.010 |
Why?
|
| Homozygote | 1 | 1994 | 119 | 0.010 |
Why?
|
| Heterozygote | 1 | 1994 | 174 | 0.010 |
Why?
|
| DNA Damage | 1 | 1995 | 190 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 1047 | 0.010 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 1992 | 7 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1992 | 78 | 0.010 |
Why?
|
| Cell Survival | 1 | 1995 | 901 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1992 | 75 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1992 | 108 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1992 | 145 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1995 | 1745 | 0.010 |
Why?
|
| Cell Line | 1 | 1995 | 1752 | 0.010 |
Why?
|
| Splenic Neoplasms | 1 | 1988 | 5 | 0.000 |
Why?
|
| Spleen | 1 | 1988 | 301 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1988 | 334 | 0.000 |
Why?
|
| Neoplasms | 1 | 1992 | 1667 | 0.000 |
Why?
|